TD Cowen has revised upward its price target for Johnson & Johnson (NYSE: JNJ), raising it from $222 to $250 while reaffirming a Buy rating on the healthcare titan’s shares. This adjustment follows the company’s solid fourth-quarter performance, which outpaced market expectations with revenue of $24.6 billion.
The firm emphasized that Johnson & Johnson’s preliminary guidance for 2026 is likely to push analysts’ revenue and earnings per share projections higher, underpinning an optimistic outlook. TD Cowen highlighted the sustained momentum anticipated in the company’s Pharmaceutical and Medical Devices segments, consistent with the gains recorded in the latter half of 2025 and expected to continue through 2026 and afterwards.
The newly set price target corresponds to approximately 20 times the firm’s forecasted earnings per share for 2027, demonstrating confidence in Johnson & Johnson’s earning power over the coming years.
In related developments, Johnson & Johnson surpassed analyst consensus by reporting fourth-quarter sales of $24.564 billion, exceeding the $24.15 billion estimate. The company’s earnings per share landed at $2.46, closely aligning with forecasts.
This strong financial performance has prompted other market players to adjust their ratings and price targets. RBC Capital upheld its Outperform rating and assigned a $240 price target, pointing out earnings per share consistent with expectations. Guggenheim reiterated its Buy rating with a price target of $227, noting that sales surpassed both their estimates and overall market consensus. Stifel revised its price target upward to $220 from $205, maintaining a Hold rating, and referenced the impressive 6.1% year-over-year organic growth and solid outcomes for 2025. Bank of America Securities modestly increased its price target to $221 with a Neutral rating, describing the results as strong, buoyed by core growth drivers and positive international market performance.
These shifts in price targets and analyst recommendations underscore the robust financial footing and strategic growth initiatives at Johnson & Johnson, reflecting a broadly positive assessment from market watchers regarding the company’s recent operational achievements.